Primary Biliary Cirrhosis

Carlo Selmi, Ross L. Coppel, M. Eric Gershwin

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

This chapter discusses clinical, pathologic, and epidemiologic features of Primary biliary cirrhosis (PBC). The diagnosis of PBC is based on three objective criteria. This triad consists of detectable serum antimitochondrial antibodies (AMA), increased enzymes indicating cholestasis for longer than 6 months, and a compatible or diagnostic liver histology. The chapter also describes the histology, autoimmune features, and epidemiology of PBC. It is noted that though genetics should be regarded as the major determinant in susceptibility to PBC, several other factors have been proposed, including a history of previous infections, comorbidity with other autoimmune diseases, and lifestyle factors, such as smoking and a high-fat diet. Furthermore, it is crucial to determine the pathogenic role of AMA in the bile duct damage of PBC. Once again, the development of an animal model appears to be the only way to provide a clear demonstration of such pathogenic mechanism. Finally, from a clinical standpoint, new clinical trials are needed to identify novel therapies in the long-term treatment of PBC.

Original languageEnglish (US)
Title of host publicationThe Autoimmune Diseases
PublisherElsevier Inc.
Pages749-765
Number of pages17
ISBN (Print)9780125959612
DOIs
StatePublished - 2006

Fingerprint

Biliary Liver Cirrhosis
Histology
Antibodies
Cholestasis
High Fat Diet
Bile Ducts
Autoimmune Diseases
Life Style
Comorbidity
Epidemiology
Animal Models
Smoking
Clinical Trials
Liver
Enzymes
Therapeutics
Infection
Serum

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Selmi, C., Coppel, R. L., & Gershwin, M. E. (2006). Primary Biliary Cirrhosis. In The Autoimmune Diseases (pp. 749-765). Elsevier Inc.. https://doi.org/10.1016/B978-012595961-2/50057-3

Primary Biliary Cirrhosis. / Selmi, Carlo; Coppel, Ross L.; Gershwin, M. Eric.

The Autoimmune Diseases. Elsevier Inc., 2006. p. 749-765.

Research output: Chapter in Book/Report/Conference proceedingChapter

Selmi, C, Coppel, RL & Gershwin, ME 2006, Primary Biliary Cirrhosis. in The Autoimmune Diseases. Elsevier Inc., pp. 749-765. https://doi.org/10.1016/B978-012595961-2/50057-3
Selmi C, Coppel RL, Gershwin ME. Primary Biliary Cirrhosis. In The Autoimmune Diseases. Elsevier Inc. 2006. p. 749-765 https://doi.org/10.1016/B978-012595961-2/50057-3
Selmi, Carlo ; Coppel, Ross L. ; Gershwin, M. Eric. / Primary Biliary Cirrhosis. The Autoimmune Diseases. Elsevier Inc., 2006. pp. 749-765
@inbook{64149aca536a4841894d6d3efaf899f9,
title = "Primary Biliary Cirrhosis",
abstract = "This chapter discusses clinical, pathologic, and epidemiologic features of Primary biliary cirrhosis (PBC). The diagnosis of PBC is based on three objective criteria. This triad consists of detectable serum antimitochondrial antibodies (AMA), increased enzymes indicating cholestasis for longer than 6 months, and a compatible or diagnostic liver histology. The chapter also describes the histology, autoimmune features, and epidemiology of PBC. It is noted that though genetics should be regarded as the major determinant in susceptibility to PBC, several other factors have been proposed, including a history of previous infections, comorbidity with other autoimmune diseases, and lifestyle factors, such as smoking and a high-fat diet. Furthermore, it is crucial to determine the pathogenic role of AMA in the bile duct damage of PBC. Once again, the development of an animal model appears to be the only way to provide a clear demonstration of such pathogenic mechanism. Finally, from a clinical standpoint, new clinical trials are needed to identify novel therapies in the long-term treatment of PBC.",
author = "Carlo Selmi and Coppel, {Ross L.} and Gershwin, {M. Eric}",
year = "2006",
doi = "10.1016/B978-012595961-2/50057-3",
language = "English (US)",
isbn = "9780125959612",
pages = "749--765",
booktitle = "The Autoimmune Diseases",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Primary Biliary Cirrhosis

AU - Selmi, Carlo

AU - Coppel, Ross L.

AU - Gershwin, M. Eric

PY - 2006

Y1 - 2006

N2 - This chapter discusses clinical, pathologic, and epidemiologic features of Primary biliary cirrhosis (PBC). The diagnosis of PBC is based on three objective criteria. This triad consists of detectable serum antimitochondrial antibodies (AMA), increased enzymes indicating cholestasis for longer than 6 months, and a compatible or diagnostic liver histology. The chapter also describes the histology, autoimmune features, and epidemiology of PBC. It is noted that though genetics should be regarded as the major determinant in susceptibility to PBC, several other factors have been proposed, including a history of previous infections, comorbidity with other autoimmune diseases, and lifestyle factors, such as smoking and a high-fat diet. Furthermore, it is crucial to determine the pathogenic role of AMA in the bile duct damage of PBC. Once again, the development of an animal model appears to be the only way to provide a clear demonstration of such pathogenic mechanism. Finally, from a clinical standpoint, new clinical trials are needed to identify novel therapies in the long-term treatment of PBC.

AB - This chapter discusses clinical, pathologic, and epidemiologic features of Primary biliary cirrhosis (PBC). The diagnosis of PBC is based on three objective criteria. This triad consists of detectable serum antimitochondrial antibodies (AMA), increased enzymes indicating cholestasis for longer than 6 months, and a compatible or diagnostic liver histology. The chapter also describes the histology, autoimmune features, and epidemiology of PBC. It is noted that though genetics should be regarded as the major determinant in susceptibility to PBC, several other factors have been proposed, including a history of previous infections, comorbidity with other autoimmune diseases, and lifestyle factors, such as smoking and a high-fat diet. Furthermore, it is crucial to determine the pathogenic role of AMA in the bile duct damage of PBC. Once again, the development of an animal model appears to be the only way to provide a clear demonstration of such pathogenic mechanism. Finally, from a clinical standpoint, new clinical trials are needed to identify novel therapies in the long-term treatment of PBC.

UR - http://www.scopus.com/inward/record.url?scp=49549118782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549118782&partnerID=8YFLogxK

U2 - 10.1016/B978-012595961-2/50057-3

DO - 10.1016/B978-012595961-2/50057-3

M3 - Chapter

AN - SCOPUS:49549118782

SN - 9780125959612

SP - 749

EP - 765

BT - The Autoimmune Diseases

PB - Elsevier Inc.

ER -